Bond Biosciences announces a successful pre-IND meeting with the FDA to advance the development of BBI-001, a treatment for iron overload in Hereditary Hemochromatosis (HH) patients. The FDA's positive feedback provides a clear pathway for the submission of an IND application in Q4 2024, paving the way for a Phase 2 clinical trial.#hemochromatosis #ironoverload Announcement details: https://lnkd.in/gPxyhV4b
Bond Biosciences
Biotechnology
Parkville, Missouri 180 followers
Discovering and developing first-in-class non-absorbed oral therapeutics to prevent and treat ion-related human diseases
About us
Bond Biosciences, Inc. is a privately held, clinical stage biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease.
- Website
-
https://bond.bio/
External link for Bond Biosciences
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Headquarters
- Parkville, Missouri
- Type
- Privately Held
Locations
-
Primary
Get directions
170 English Landing Dr
Suite 201B
Parkville, Missouri 64152, US
Employees at Bond Biosciences
Updates
-
Bond Biosciences reposted this
Bond Biosciences is excited to announce its participation in the Biotech Showcase™ 2024, coinciding with the JPMorgan 42nd Annual Healthcare Conference in San Francisco. During this event, Bond will deliver a comprehensive corporate update, unveiling results from the Phase 1b trial assessing the efficacy of BBI-001. For a deeper understanding of the Biotech Showcase, the groundbreaking BBI-001, and the latest developments at Bond Biosciences, we invite you to explore our announcement. #hemochromatosis #ironoverload Announcement details: https://lnkd.in/gg7GHCnC
Bond Biosciences Announces Positive Phase Ia/b Pharmacodynamic and Safety Data for BBI-001, a Novel, Non-Absorbed, Oral Therapy for Iron Overload
businesswire.com
-
Bond Biosciences is excited to announce its participation in the Biotech Showcase™ 2024, coinciding with the JPMorgan 42nd Annual Healthcare Conference in San Francisco. During this event, Bond will deliver a comprehensive corporate update, unveiling results from the Phase 1b trial assessing the efficacy of BBI-001. For a deeper understanding of the Biotech Showcase, the groundbreaking BBI-001, and the latest developments at Bond Biosciences, we invite you to explore our announcement. #hemochromatosis #ironoverload Announcement details: https://lnkd.in/gg7GHCnC
Bond Biosciences Announces Positive Phase Ia/b Pharmacodynamic and Safety Data for BBI-001, a Novel, Non-Absorbed, Oral Therapy for Iron Overload
businesswire.com